Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with ⁹⁰Y resin microspheres for chemo-refractory colorectal liver metastases.

ABSTRACT:

Background

Extrahepatic disease progression limits clinical efficacy of Yttrium-90 (⁹⁰Y) radioembolization (TARE) for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Trifluridine and tipiracil (TAS-102) has overall survival benefit for patients with refractory mCRC and may be a radiosensitizer.

Methods

Sequential lobar TARE using ⁹⁰Y resin microspheres in combination with TAS-102 in 28-day cycles were used to treat adult patients with bilobar liver-dominant chemo-refractory mCRC according to 3 + 3 dose escalation design with a 12-patient dose expansion cohort. Study objectives were to establish safety and determine maximum tolerated dose (MTD) of TAS-102 in combination with TARE.

Results

A total of 21 patients (14 women

SUBMITTER: Fidelman N 

PROVIDER: S-EPMC9749246 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature